Compare Teucrium Corn Fund (CORN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teucrium Corn Fund vs State Street SPDR S&P Biotech ETF — how do they compare? Teucrium Corn Fund trades at $17.51, while State Street SPDR S&P Biotech ETF trades at $155.14. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Teucrium Corn Fund nearer its low. Which is the better fit depends on your goals.
| CORN | XBI | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Broad Market / Factor |
52-Week High | $19.12 | $164.28 |
52-Week Low | $16.46 | $85.16 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $155.34, down 2.32% on the day, but maintains a bullish technical outlook with strong momentum indicators. The biotech ETF has gained significant attention after a 17% monthly surge, driven by sector rotation and M&A activity. Analyst coverage remains limited with a single hold rating, though recent news highlights biotech's strong performance amid market volatility.
The ETF offers exposure to biotech's resurgence with AI drug discovery and deal momentum as catalysts. However, high volatility and concentrated sector risk require careful position sizing. Current technical strength suggests potential for continued upside if sector momentum persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Teucrium Corn Fund
CORN is a commodity ETF that provides exposure to the price of corn futures. It uses a laddered investment strategy across multiple benchmark contracts to help minimize the impact of contango and roll costs in the agricultural market.
Read more on CORN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
